Phase II study to evaluate the safety and efficacy of endoscopic radiofrequency ablation of the bile duct using the Habib Endo HPB catheter in patients with unresectable cholangiocarcinoma after biliary stent placement.
Not Applicable
- Conditions
- Cholangiocarcinoma
- Registration Number
- JPRN-UMIN000047127
- Lead Sponsor
- Yokohama City University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 10
Inclusion Criteria
Not provided
Exclusion Criteria
(1) Patients in poor general condition who cannot undergo endoscopy (2) Patients taking more than 2 antiplatelet/anticoagulant drugs (3) Patients with a pacemaker implanted (4) Patients with a fever of 37.5 or higher and suspected cholangitis (5) Other patients deemed unsuitable for the procedure by the physician
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method All adverse events within 28 days after ERCP, including endoscopic RFA procedures
- Secondary Outcome Measures
Name Time Method RFA procedure success rate, stent patency after RFA, and overall survival